Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)

• DOI: 10.1186/s12879-022-07570-5
• Publication Date: 2022-07-09T07:02:59Z
• Authors: Nirmal Ghati; Sushma Bhatnagar; Manjit Mahendran; Abhishek Thakur; Kshitij Prasad; Devesh Kumar; Tanima Dwivedi; Kalaivani Mani; Pawan Tiwari; Ritu Gupta; Anant Mohan; Anita Saxena; Randeep Guleria; Siddharthan Deepti
• Keywords: 0303 health sciences; Aspirin; Clinical Deterioration; Interleukin-6; SARS-CoV-2; Research; COVID-19; Statin; WHO ordinal scale; Infectious and parasitic diseases; RC109-216; COVID-19 Drug Treatment; 3. Good health; 03 medical and health sciences; Serum IL-6; Treatment Outcome; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Abstract Background Statins and aspirin have been proposed for treatment of COVID-19 because their anti-inflammatory anti-thrombotic properties. Several observational studies shown favourable results. There is a need randomised controlled trial. Methods In this single-center, open-label, trial, 900 RT-PCR positive patients requiring hospitalisation, were randomly assigned to receive either atorvastatin 40 mg (Group A, n = 224), 75 B, 225), or both C, 225) in addition standard care 10 days until discharge whichever was earlier only D, 226). The primary outcome variable clinical deterioration WHO Ordinal Scale Clinical Improvement ≥ 6. secondary change serum C-reactive protein, interleukin-6, troponin I. Results occurred 25 (2.8%) patients: 7 (3.2%) Group 3 (1.4%) 8 (3.6%) D. no difference across the study groups (P 0.463). Comparison all who received with control group D) also did not show any benefit [Atorvastatin: HR 1.0 (95% CI 0.41–2.46) P 0.99; Aspirin: 0.7 0.27–1.81) 0.46]. outcomes revealed lower interleukin-6 levels among Groups B C. excess adverse events. Conclusions Among admitted mild moderate infection, additional aspirin, atorvastatin, combination two does prevent deterioration. Trial Registry Number CTRI/2020/07/026791 ( http://ctri.nic.in ; registered on 25/07/2020)